K2 Principal Fund’s NRX Pharmaceuticals NRXP Stock Holding History

K2 Principal Fund’s Portfolio NRXP Stock Details NRXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-19,309	Closed	-$2.05M	–	289
2019 Q4	$2.05M	Hold	19,309	–	–	0.18%	158
2019 Q3	$2.04M	Hold	19,309	–	–	0.22%	156
2019 Q2	$2.01M	Hold	19,309	–	–	0.24%	145
2019 Q1	$2M	Hold	19,309	–	–	0.25%	130
2018 Q4	$1.97M	Buy	19,309 +5,890	+44%	+$595K	0.3%	123
2018 Q3	$1.34M	Sell	13,419 -1,220	-8%	-$121K	0.13%	185
2018 Q2	$1.45M	Hold	14,639	–	–	0.11%	195
2018 Q1	$1.43M	Buy	14,639 +7,121	+95%	+$694K	0.08%	204
2017 Q4	$728K	Buy	+7,518	New	+$727K	0.05%	217

Other funds holding NRXP

RCM

Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

PMAM

Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 51.47% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $351M AUM 21.8% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BCM

Bluefin Capital Management New York $156M AUM 18.42% 1-Year Est. Return

Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

K2 Principal Fund's NRXP Position: Q1 2020 in Review

K2 Principal Fund sold out of NRX Pharmaceuticals (NRXP) in Q1 2020, closing a stake of 19,309 shares — an estimated $2.05M sold.

K2 Principal Fund first reported a position in NRXP in Q4 2017 and held it in 9 quarters. The position peaked at $2.05M in Q4 2019. 7 funds tracked by Wall St. Rank hold NRXP as of Q1 2020.

K2 Principal Fund reported no remaining NRX Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
K2 Principal Fund sold 19,309 NRX Pharmaceuticals shares in Q1 2020, an estimated $2.05M.
K2 Principal Fund first reported a position in NRX Pharmaceuticals in Q4 2017 and held it in 9 quarters.
K2 Principal Fund's NRX Pharmaceuticals position peaked at $2.05M in Q4 2019.
7 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q1 2020.

Based on K2 Principal Fund's 13F filing for Q1 2020, filed 15 May 2020.